SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001144204-19-016097
Filing Date
2019-03-27
Accepted
2019-03-27 08:32:37
Documents
12
Period of Report
2019-03-27

Document Format Files

Seq Description Document Type Size
1 FORM 6-K tv516517_6k.htm 6-K 191804
2 EXHIBIT 99.1 tv516517_ex99-1.htm EX-99.1 118573
3 EXHIBIT 99.2 tv516517_ex99-2.htm EX-99.2 164612
4 EXHIBIT 99.3 tv516517_ex99-3.htm EX-99.3 378502
5 EXHIBIT 99.4 tv516517_ex99-4.htm EX-99.4 436282
6 EXHIBIT 99.5 tv516517_ex99-5.htm EX-99.5 3514
7 EXHIBIT 99.6 tv516517_ex99-6.htm EX-99.6 13455
8 GRAPHIC image_001.jpg GRAPHIC 9776
9 GRAPHIC image_002.jpg GRAPHIC 9814
10 GRAPHIC image_003.jpg GRAPHIC 10006
11 GRAPHIC image_006.jpg GRAPHIC 7192
12 GRAPHIC image_008.jpg GRAPHIC 8336
  Complete submission text file 0001144204-19-016097.txt   1370825
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 19706715
SIC: 2834 Pharmaceutical Preparations